# Qure.AI
Qure.AI is a Mumbai-based healthtech company, founded in 2016, that builds artificial intelligence software to read and triage medical images, chiefly chest X-rays and head CT scans. Its products hold US FDA clearances and EU MDR Class IIb certification, and in September 2024 it closed a $65 million Series D led by Lightspeed Venture Partners and 360 ONE Asset Management.[1](https://economictimes.indiatimes.com/tech/funding/lightspeed-leads-65-million-round-by-india-ai-diagnostics-startup-qure-ai/articleshow/113607128.cms) • [2](https://www.globenewswire.com/news-release/2024/09/25/2953204/0/en/Global-healthcare-AI-innovator-Qure-ai-completes-65-million-Series-D-funding-round-led-by-Lightspeed-and-360One-Asset.html)
| Fact | Detail |
|---|---|
| Founded | 2016, Mumbai, India[1](https://economictimes.indiatimes.com/tech/funding/lightspeed-leads-65-million-round-by-india-ai-diagnostics-startup-qure-ai/articleshow/113607128.cms) |
| Founders | Prashant Warier (AI entrepreneur) and Dr. Pooja Rao (physician-data scientist)[3](https://yespress.io/qure-ai) |
| What it does | AI software that detects and triages disease on chest X-rays and head CT scans[4](https://www.accessdata.fda.gov/cdrh_docs/pdf20/K200921.pdf) |
| Main products | qXR (chest X-ray), qER (head CT), qTrack (care coordination)[4](https://www.accessdata.fda.gov/cdrh_docs/pdf20/K200921.pdf) • [5](https://www.qure.ai/) |
| Series D | $65 million, September 25, 2024, led by Lightspeed, and 360 ONE Asset[2](https://www.globenewswire.com/news-release/2024/09/25/2953204/0/en/Global-healthcare-AI-innovator-Qure-ai-completes-65-million-Series-D-funding-round-led-by-Lightspeed-and-360One-Asset.html) |
| Footprint | 3,000+ imaging sites in over 90 countries (Sept 2024); reported 5,500+ sites in 105+ countries by 2026 (partly company-supplied)[1](https://economictimes.indiatimes.com/tech/funding/lightspeed-leads-65-million-round-by-india-ai-diagnostics-startup-qure-ai/articleshow/113607128.cms) • [3](https://yespress.io/qure-ai) |
| Regulatory | 18 FDA-cleared indications (Sept 2024), reported 26 across nine products by Feb 2026; EU MDR Class IIb certified[2](https://www.globenewswire.com/news-release/2024/09/25/2953204/0/en/Global-healthcare-AI-innovator-Qure-ai-completes-65-million-Series-D-funding-round-led-by-Lightspeed-and-360One-Asset.html) • [3](https://yespress.io/qure-ai) |
## Founders and origins
Qure.AI was founded in Mumbai in 2016 by Prashant Warier, an AI entrepreneur, and Dr. Pooja Rao, a physician and data scientist.[3](https://yespress.io/qure-ai) The company says it raised Series A funding from [Sequoia Capital](https://www.edgepedia.org/sequoia-capital) and MassMutual Ventures.[6](https://www.qure.ai/us/about-us)
## Products, technology and how the AI works
The company's two flagship products are **qER** and **qXR**. **qER** is a deep-learning software device that analyses non-contrast head CT scans for signs of intracranial hemorrhage, midline shift, mass effect, or cranial fractures, in order to prioritize them for clinical review.[4](https://www.accessdata.fda.gov/cdrh_docs/pdf20/K200921.pdf)
**qXR** analyses chest radiographs. Its qXR-Detect variant is a computer-assisted detection (CADe) device that highlights suspicious regions of interest.[7](https://www.accessdata.fda.gov/cdrh_docs/pdf25/K251934.pdf) The underlying algorithm was trained on approximately 2.5 million chest X-ray scans from the US, EU, India, Vietnam, and Brazil.[7](https://www.accessdata.fda.gov/cdrh_docs/pdf25/K251934.pdf) A 2026 peer-reviewed evaluation of the qXR lung nodule model states it was trained on over 3.5 million chest X-rays and validated on more than 13,000; the two figures refer to different versions and filings and the sources do not reconcile them.[8](https://doi.org/10.1016/j.mcpdig.2026.100335)
Beyond the flagship pair, the company offers qTrack, an AI-powered care coordination suite for patient triage and real-time communication that supports [Hub & Spoke](https://www.edgepedia.org/spoke-hub-distribution-paradigm) networks for timely stroke interventions, and a lung cancer suite covering the care continuum from early nodule detection to progression measurement.[5](https://www.qure.ai/) The company says its WHO-evaluated solutions support tuberculosis, silicosis, and pediatric TB diagnosis, and real-time disease surveillance.[5](https://www.qure.ai/)
## Regulatory approvals and clinical evidence
The FDA cleared qER as Class II radiological computer-assisted triage and notification software for non-contrast head CT.[4](https://www.accessdata.fda.gov/cdrh_docs/pdf20/K200921.pdf) qXR-Detect was cleared with a decision letter dated June 24, 2025.[7](https://www.accessdata.fda.gov/cdrh_docs/pdf25/K251934.pdf) As of September 2024 the company reported 18 FDA-cleared indications in total, with products certified Class IIb under EU MDR regulations; it also says it received WHO endorsement for its chest X-ray solution for TB screening to be used in the absence of a human reader.[2](https://www.globenewswire.com/news-release/2024/09/25/2953204/0/en/Global-healthcare-AI-innovator-Qure-ai-completes-65-million-Series-D-funding-round-led-by-Lightspeed-and-360One-Asset.html) • [6](https://www.qure.ai/us/about-us)
On clinical performance, the CREATE study reported that qXR's deep-learning algorithm achieved 84.1% sensitivity and a scan-level AUC of 94.5 for detecting pulmonary nodules sized 6 to 30 mm.[8](https://doi.org/10.1016/j.mcpdig.2026.100335) Multi-reader studies in the same publication showed a statistically significant improvement in lung nodule detection with AI assistance, with the alternative free-response receiver operating characteristic (AFROC) metric increasing by 0.076 (p < 1×10⁻⁵).[8](https://doi.org/10.1016/j.mcpdig.2026.100335)
## Funding history and investors
The Series D, announced as completed on September 25, 2024, raised $65 million and was led by Lightspeed and 360 ONE Asset, joined by Merck Global Health Innovation Fund and [Kae Capital](https://www.edgepedia.org/kae-capital), with existing investors Novo Holdings, Health Quad, and TeamFund participating.[2](https://www.globenewswire.com/news-release/2024/09/25/2953204/0/en/Global-healthcare-AI-innovator-Qure-ai-completes-65-million-Series-D-funding-round-led-by-Lightspeed-and-360One-Asset.html) • [9](https://yourstory.com/2024/09/funding-global-healthcare-ai-startup-qureai-65-m-seriesd-round)
Earlier rounds are less well documented in reliable sources. The company says its Series A came from Sequoia Capital and MassMutual Ventures.[6](https://www.qure.ai/us/about-us) A 2026 profile reports roughly $130 million in total capital raised, a figure partly company-supplied and not independently verified.[3](https://yespress.io/qure-ai)
## Deployments, traction and partnerships
At the time of the Series D, Qure.AI's products were deployed in over 90 countries across more than 3,000 imaging sites.[1](https://economictimes.indiatimes.com/tech/funding/lightspeed-leads-65-million-round-by-india-ai-diagnostics-startup-qure-ai/articleshow/113607128.cms) By 2026, a profile reported more than 5,500 sites in 105-plus countries, a figure partly company-supplied.[3](https://yespress.io/qure-ai) The company says it partnered with [AstraZeneca](https://www.edgepedia.org/astrazeneca) specifically for lung cancer screening using its chest X-ray solution.[6](https://www.qure.ai/us/about-us) It is headquartered in Mumbai, with regional offices in New York, London, and Dubai.[2](https://www.globenewswire.com/news-release/2024/09/25/2953204/0/en/Global-healthcare-AI-innovator-Qure-ai-completes-65-million-Series-D-funding-round-led-by-Lightspeed-and-360One-Asset.html)
## References
1. [Lightspeed leads $65 million round by India AI diagnostics startup Qure AI – Economic Times](https://economictimes.indiatimes.com/tech/funding/lightspeed-leads-65-million-round-by-india-ai-diagnostics-startup-qure-ai/articleshow/113607128.cms)
2. [Qure.ai completes $65 million Series D funding round – GlobeNewswire](https://www.globenewswire.com/news-release/2024/09/25/2953204/0/en/Global-healthcare-AI-innovator-Qure-ai-completes-65-million-Series-D-funding-round-led-by-Lightspeed-and-360One-Asset.html)
3. [Qure.ai Learned the Hard Part of Medical AI Isn't Reading the Scan – YesPress](https://yespress.io/qure-ai)
4. [FDA 510(k) Summary K200921 – qER (Qure.AI Technologies)](https://www.accessdata.fda.gov/cdrh_docs/pdf20/K200921.pdf)
5. [Qure AI | AI assistance for Accelerated Healthcare](https://www.qure.ai/)
6. [About Us | Qure AI](https://www.qure.ai/us/about-us)
7. [FDA 510(k) K251934 – qXR-Detect (Qure.AI Technologies)](https://www.accessdata.fda.gov/cdrh_docs/pdf25/K251934.pdf)
8. [Evaluation of an Artificial Intelligence Defined Lung Nodule Malignancy Score in Incidental Pulmonary Nodules: The CREATE Study](https://doi.org/10.1016/j.mcpdig.2026.100335)
9. [Qure.ai raises $65M in Series D round – YourStory](https://yourstory.com/2024/09/funding-global-healthcare-ai-startup-qureai-65-m-seriesd-round)
---
*Topic: Encyclopedia › Society and history › Economics and business › Business and work › Business and work overview › Companies and corporations › Venture-backed startups and growth companies › Health, biotech, and medtech startups › Digital health and health IT companies › Health IT and services software*
*Initially written Sep 17, 2026 · Edited: Oct 11, 2026; Oct 15, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license